Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients
Journal of Applied Microbiology2022Vol. 133(5), pp. 2826–2834
Citations Over Time
Abstract
HCV RASs have been studied very well across the world but there is scarcity of data regarding this topic in Pakistani population, this study provides data regarding the prevalence of these RASs in Pakistani HCV isolates emphasizing the fact that these RASs must be carefully monitored before starting HCV treatment, especially in treatment failure patients.
Related Papers
- → Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection(2014)1,191 cited
- → Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials(2014)213 cited
- → Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients(2022)6 cited
- → Sofosbuvir and daclatasvir(2016)8 cited
- → Sofosbuvir (Sovaldi): The First‐in‐Class HCV NS5B Nucleotide Polymerase Inhibitor(2015)11 cited